From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.

IF 4.7 2区医学 Q1 ONCOLOGY Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-05 DOI:10.1007/s11912-024-01555-0

Joshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, Sijie Yao, G Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M Gilbert, Michael A Poch, Wade J Sexton, Philippe E Spiess, Roger Li

{"title":"From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.","authors":"Joshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, Sijie Yao, G Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M Gilbert, Michael A Poch, Wade J Sexton, Philippe E Spiess, Roger Li","doi":"10.1007/s11912-024-01555-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the focus is on recent studies, highlighting how utDNA could aid personalized care.Recent findings: Recent research underscores the potential for utDNA to be the premiere biomarker in bladder cancer due to the constant interface between urine and tumor. Many studies find utDNA to be more informative than other biomarkers in bladder cancer, especially in early stages of disease. Points of emphasis include superior sensitivity over traditional urine cytology, broad genomic and epigenetic insights, and the potential for non-invasive, real-time analysis of tumor biology. utDNA shows promise for improving all phases of bladder cancer care, paving the way for personalized treatment strategies. Building from current research, future comprehensive clinical trials will validate utDNA's clinical utility, potentially revolutionizing bladder cancer management.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01555-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the focus is on recent studies, highlighting how utDNA could aid personalized care.

Recent findings: Recent research underscores the potential for utDNA to be the premiere biomarker in bladder cancer due to the constant interface between urine and tumor. Many studies find utDNA to be more informative than other biomarkers in bladder cancer, especially in early stages of disease. Points of emphasis include superior sensitivity over traditional urine cytology, broad genomic and epigenetic insights, and the potential for non-invasive, real-time analysis of tumor biology. utDNA shows promise for improving all phases of bladder cancer care, paving the way for personalized treatment strategies. Building from current research, future comprehensive clinical trials will validate utDNA's clinical utility, potentially revolutionizing bladder cancer management.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

从检测到治愈--尿液肿瘤 DNA (utDNA) 在膀胱癌中的新作用。

综述的目的：本综述旨在确定尿液肿瘤 DNA（utDNA）在诊断、监测和治疗膀胱癌方面的新作用。在早期标志性研究的基础上，重点关注近期的研究，突出utDNA如何帮助个性化治疗：最近的研究强调，由于尿液和肿瘤之间的持续接触，utDNA 有可能成为膀胱癌的首要生物标志物。许多研究发现，utDNA 比其他膀胱癌生物标记物更有参考价值，尤其是在疾病的早期阶段。utDNA有望改善膀胱癌治疗的各个阶段，为个性化治疗策略铺平道路。在目前研究的基础上，未来的综合临床试验将验证 utDNA 的临床实用性，从而有可能彻底改变膀胱癌的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.